Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2)

Drug Discovery Today

Volumn 6, Issue 4, 2001, Pages 206-212

  Kusuhara, Hiroyuki ^a   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHYL BETA GLUCURONIDE; 2,4 DICHLOROPHENOXYACETIC ACID; 4 AMINOHIPPURIC ACID; 5 AMINO 7 (7 AMINO 5 AZASPIRO[2.4]HEPT 5 YL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHYL 4 OXO 3 QUINOLINECARBOXYLIC ACID; ASIMADOLINE; COLCHICINE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOPEPTIDE; CYCLOSPORIN A; DEXAMETHASONE; DIDANOSINE; DIGOXIN; DOXORUBICIN; GLYCOPROTEIN P; GREPAFLOXACIN; INDINAVIR; IVERMECTIN; LOPERAMIDE; MORPHINE; ONDANSETRON; PENICILLIN G; PROGESTERONE; QUINIDINE; SPARFLOXACIN; TACROLIMUS; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINCRISTINE; ZIDOVUDINE;

BLOOD BRAIN BARRIER; BRAIN; BRAIN ISCHEMIA; CATTLE; CEREBROSPINAL FLUID; CHOROID PLEXUS; DRUG CLEARANCE; DRUG CONJUGATION; DRUG ELIMINATION; DRUG TRANSPORT; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; IN VITRO STUDY; KNOCKOUT MOUSE; NONHUMAN; REVIEW; TECHNIQUE;

EID: 0035254189     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(00)01643-3     Document Type: Review

References (46)

1. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1).
2. In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier.
3. In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier.
4. Transport of small molecules through the blood-brain barrier: biology and methodology.
5. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells.
6. Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain epididymal fat pad and from aorta.
7. Functional involvement of P-glycoprotein in blood-brain barrier.
8. Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein.
9. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.
10. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.
11. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism.
12. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity.
13. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice.
14. BBB transport and P-glycoprotein functionality using MDR1A (-/-) and wild-type mice. Total brain versus microdialysis concentration profiles of rhodamine-123.
15. P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier.
16. Efflux transport of a new quinolone antibacterial agent, HSR903 across the blood-brain barrier.
17. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography.
18. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
19. In vivo study of the elimination from rat brain of an intracerebrally formed xenobiotic metabolite 1-naphthyl-(-d-glucuronide.
20. Saturable efflux of the peptides RC160 and Tyr-MIF-1 by different parts of the blood-brain barrier.
21. Selective brain to blood efflux transport of para-aminohippuric acid across the blood-brain barrier: in vivo evidence by use of the brain efflux index method.
22. In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′3′-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system.
23. Efflux of taurocholic acid across the blood-brain barrier: interaction with cyclic peptides.
24. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver.
25. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line.
26. High-affinity efflux transport system for glutathione conjugates on the luminal membrane of a mouse brain capillary endothelial cell line (MBEC4).
27. Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the CNS.
28. Drug transport in the mammalian CNS: multiple complex systems. A critical analysis and commentary.
29. Transepithelial transport of organic anions across the choroid plexus: possible involvement of organic anion transporter and multidrug resistance-associated protein.
30. Mechanism of organic anion transport across the apical membrane of choroid plexus.
31. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein.
32. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.
33. Characterization of the transport properties of a quinolone antibiotic, fleroxacin in rat choroid plexus.
34. Transport of cefodizime, a novel third generation cephalosporin antibiotic in isolated rat choroid plexus.
35. Active transport properties of porcine choroid plexus cells in culture.
36. Saturable accumulation of the anionic herbicide, 2,4-dichlorophenoxyacetic acid (2,4D) by rabbit choroid plexus: early developmental origin and interaction with salicylates.
37. Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs.
38. Demonstration of a coupled metabolism-efflux process at the choroid plexus as a mechanism of brain protection toward xenobiotics.
39. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side effects of asimadoline a peripherally acting analgesic drug.
40. Absence of the Mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone digoxin and cyclosporin A.
41. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein deficient mice.
42. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in Mdr1 knockout mice.
43. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier.
44. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
45. Multidrug resistance and the role of P-glycoprotein knockout mice.
46. Effect of the Mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent in mice.